Report Overview
Report Overview
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Companion Diagnostics for Oncology market size was estimated at USD 4977.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 10.80% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Companion Diagnostics for Oncology market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Companion Diagnostics for Oncology market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Companion Diagnostics for Oncology market.
Global Companion Diagnostics for Oncology Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Agilent Technologies
Illumina
Roche
BioMérieux
Foundation Medicine
ArcherDX
Qiagen
Thermo Fisher Scientific
Amoy Diagnostics
Abbott
Market Segmentation (by Type)
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Market Segmentation (by Application)
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Companion Diagnostics for Oncology Market
Overview of the regional outlook of the Companion Diagnostics for Oncology Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Companion Diagnostics for Oncology Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the markets competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Companion Diagnostics for Oncology, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Table of Contents
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Companion Diagnostics for Oncology
- 1.2 Key Market Segments
- 1.2.1 Companion Diagnostics for Oncology Segment by Type
- 1.2.2 Companion Diagnostics for Oncology Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Companion Diagnostics for Oncology Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Companion Diagnostics for Oncology Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global Companion Diagnostics for Oncology Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 2.1 Global Market Overview
- 3 Companion Diagnostics for Oncology Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Companion Diagnostics for Oncology Product Life Cycle
- 3.3 Global Companion Diagnostics for Oncology Sales by Manufacturers (2020-2025)
- 3.4 Global Companion Diagnostics for Oncology Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Companion Diagnostics for Oncology Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Companion Diagnostics for Oncology Market Competitive Situation and Trends
- 3.8.1 Companion Diagnostics for Oncology Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Companion Diagnostics for Oncology Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Companion Diagnostics for Oncology Industry Chain Analysis
- 4.1 Companion Diagnostics for Oncology Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Companion Diagnostics for Oncology Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Companion Diagnostics for Oncology Market Porters Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Companion Diagnostics for Oncology Market
- 5.7 ESG Ratings of Leading Companies
- 6 Companion Diagnostics for Oncology Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Companion Diagnostics for Oncology Sales Market Share by Type (2020-2025)
- 6.3 Global Companion Diagnostics for Oncology Market Size by Type (2020-2025)
- 6.4 Global Companion Diagnostics for Oncology Price by Type (2020-2025)
- 7 Companion Diagnostics for Oncology Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Companion Diagnostics for Oncology Market Sales by Application (2020-2025)
- 7.3 Global Companion Diagnostics for Oncology Market Size (M USD) by Application (2020-2025)
- 7.4 Global Companion Diagnostics for Oncology Sales Growth Rate by Application (2020-2025)
- 8 Companion Diagnostics for Oncology Market Sales by Region
- 8.1 Global Companion Diagnostics for Oncology Sales by Region
- 8.1.1 Global Companion Diagnostics for Oncology Sales by Region
- 8.1.2 Global Companion Diagnostics for Oncology Sales Market Share by Region
- 8.2 Global Companion Diagnostics for Oncology Market Size by Region
- 8.2.1 Global Companion Diagnostics for Oncology Market Size by Region
- 8.2.2 Global Companion Diagnostics for Oncology Market Size by Region
- 8.3 North America
- 8.3.1 North America Companion Diagnostics for Oncology Sales by Country
- 8.3.2 North America Companion Diagnostics for Oncology Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Companion Diagnostics for Oncology Sales by Country
- 8.4.2 Europe Companion Diagnostics for Oncology Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Companion Diagnostics for Oncology Sales by Region
- 8.5.2 Asia Pacific Companion Diagnostics for Oncology Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Companion Diagnostics for Oncology Sales by Country
- 8.6.2 South America Companion Diagnostics for Oncology Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Companion Diagnostics for Oncology Sales by Region
- 8.7.2 Middle East and Africa Companion Diagnostics for Oncology Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 8.1 Global Companion Diagnostics for Oncology Sales by Region
- 9 Companion Diagnostics for Oncology Market Production by Region
- 9.1 Global Production of Companion Diagnostics for Oncology by Region(2020-2025)
- 9.2 Global Companion Diagnostics for Oncology Revenue Market Share by Region (2020-2025)
- 9.3 Global Companion Diagnostics for Oncology Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Companion Diagnostics for Oncology Production
- 9.4.1 North America Companion Diagnostics for Oncology Production Growth Rate (2020-2025)
- 9.4.2 North America Companion Diagnostics for Oncology Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Companion Diagnostics for Oncology Production
- 9.5.1 Europe Companion Diagnostics for Oncology Production Growth Rate (2020-2025)
- 9.5.2 Europe Companion Diagnostics for Oncology Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Companion Diagnostics for Oncology Production (2020-2025)
- 9.6.1 Japan Companion Diagnostics for Oncology Production Growth Rate (2020-2025)
- 9.6.2 Japan Companion Diagnostics for Oncology Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Companion Diagnostics for Oncology Production (2020-2025)
- 9.7.1 China Companion Diagnostics for Oncology Production Growth Rate (2020-2025)
- 9.7.2 China Companion Diagnostics for Oncology Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Agilent Technologies
- 10.1.1 Agilent Technologies Basic Information
- 10.1.2 Agilent Technologies Companion Diagnostics for Oncology Product Overview
- 10.1.3 Agilent Technologies Companion Diagnostics for Oncology Product Market Performance
- 10.1.4 Agilent Technologies Business Overview
- 10.1.5 Agilent Technologies SWOT Analysis
- 10.1.6 Agilent Technologies Recent Developments
- 10.2 Illumina
- 10.2.1 Illumina Basic Information
- 10.2.2 Illumina Companion Diagnostics for Oncology Product Overview
- 10.2.3 Illumina Companion Diagnostics for Oncology Product Market Performance
- 10.2.4 Illumina Business Overview
- 10.2.5 Illumina SWOT Analysis
- 10.2.6 Illumina Recent Developments
- 10.3 Roche
- 10.3.1 Roche Basic Information
- 10.3.2 Roche Companion Diagnostics for Oncology Product Overview
- 10.3.3 Roche Companion Diagnostics for Oncology Product Market Performance
- 10.3.4 Roche Business Overview
- 10.3.5 Roche SWOT Analysis
- 10.3.6 Roche Recent Developments
- 10.4 BioMérieux
- 10.4.1 BioMérieux Basic Information
- 10.4.2 BioMérieux Companion Diagnostics for Oncology Product Overview
- 10.4.3 BioMérieux Companion Diagnostics for Oncology Product Market Performance
- 10.4.4 BioMérieux Business Overview
- 10.4.5 BioMérieux Recent Developments
- 10.5 Foundation Medicine
- 10.5.1 Foundation Medicine Basic Information
- 10.5.2 Foundation Medicine Companion Diagnostics for Oncology Product Overview
- 10.5.3 Foundation Medicine Companion Diagnostics for Oncology Product Market Performance
- 10.5.4 Foundation Medicine Business Overview
- 10.5.5 Foundation Medicine Recent Developments
- 10.6 ArcherDX
- 10.6.1 ArcherDX Basic Information
- 10.6.2 ArcherDX Companion Diagnostics for Oncology Product Overview
- 10.6.3 ArcherDX Companion Diagnostics for Oncology Product Market Performance
- 10.6.4 ArcherDX Business Overview
- 10.6.5 ArcherDX Recent Developments
- 10.7 Qiagen
- 10.7.1 Qiagen Basic Information
- 10.7.2 Qiagen Companion Diagnostics for Oncology Product Overview
- 10.7.3 Qiagen Companion Diagnostics for Oncology Product Market Performance
- 10.7.4 Qiagen Business Overview
- 10.7.5 Qiagen Recent Developments
- 10.8 Thermo Fisher Scientific
- 10.8.1 Thermo Fisher Scientific Basic Information
- 10.8.2 Thermo Fisher Scientific Companion Diagnostics for Oncology Product Overview
- 10.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Product Market Performance
- 10.8.4 Thermo Fisher Scientific Business Overview
- 10.8.5 Thermo Fisher Scientific Recent Developments
- 10.9 Amoy Diagnostics
- 10.9.1 Amoy Diagnostics Basic Information
- 10.9.2 Amoy Diagnostics Companion Diagnostics for Oncology Product Overview
- 10.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Product Market Performance
- 10.9.4 Amoy Diagnostics Business Overview
- 10.9.5 Amoy Diagnostics Recent Developments
- 10.10 Abbott
- 10.10.1 Abbott Basic Information
- 10.10.2 Abbott Companion Diagnostics for Oncology Product Overview
- 10.10.3 Abbott Companion Diagnostics for Oncology Product Market Performance
- 10.10.4 Abbott Business Overview
- 10.10.5 Abbott Recent Developments
- 10.1 Agilent Technologies
- 11 Companion Diagnostics for Oncology Market Forecast by Region
- 11.1 Global Companion Diagnostics for Oncology Market Size Forecast
- 11.2 Global Companion Diagnostics for Oncology Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Companion Diagnostics for Oncology Market Size Forecast by Country
- 11.2.3 Asia Pacific Companion Diagnostics for Oncology Market Size Forecast by Region
- 11.2.4 South America Companion Diagnostics for Oncology Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Companion Diagnostics for Oncology by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global Companion Diagnostics for Oncology Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of Companion Diagnostics for Oncology by Type (2026-2035)
- 12.1.2 Global Companion Diagnostics for Oncology Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of Companion Diagnostics for Oncology by Type (2026-2035)
- 12.2 Global Companion Diagnostics for Oncology Market Forecast by Application (2026-2035)
- 12.2.1 Global Companion Diagnostics for Oncology Sales (K Units) Forecast by Application
- 12.2.2 Global Companion Diagnostics for Oncology Market Size (M USD) Forecast by Application (2026-2035)
- 12.1 Global Companion Diagnostics for Oncology Market Forecast by Type (2026-2035)
- 13 Conclusion and Key Findings